Renaissance Capital logo

Gyroscope Therapeutics Holdings Postponed, Nasdaq: VISN

UK-based Phase 2 biotech developing gene therapies for ocular diseases.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a global clinical-stage gene therapy company developing gene therapy beyond rare diseases. Our mission is to preserve sight and fight the devastating impact of blindness. Our science is grounded in the genetic understanding of patients with serious eye diseases to make medicines designed to have a meaningful impact. Our initial focus is age-related macular degeneration, or AMD, one of the leading causes of irreversible blindness, affecting more than 196 million people worldwide. We are developing a differentiated pipeline of recombinant adeno-associated virus, or rAAV, gene therapy candidates targeting genetic variants in the complement pathway that we believe to be key drivers of AMD. Our investigational gene therapies are designed as one-time treatments. Our lead investigational gene therapy, GT005, is advancing in an ongoing Phase I/II clinical trial and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with geographic atrophy, or GA, an advanced form of dry AMD. We have received Fast Track designation from the U.S. Food and Drug Administration, or the FDA, for GT005 for the treatment of GA secondary to AMD.
more less
IPO News for Gyroscope Therapeutics Holdings
more
IPO Data
IPO File Date 04/16/2021
Offer Price
Price Range $20.00 - $22.00
Offer Shares (mm) 6.8
Deal Size ($mm) $142
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $20.00 - $22.00
Offer Shares (mm) 6.8
Deal Size ($mm) $142
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Hertfordshire, United Kingdom
Founded 2016
Employees 167
Website www.gyroscopetx.com